Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
|
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [31] A nonlinear optimal control problem with an application to optimal dosing of cytotoxic drugs
    Novak, Andrej
    CHAOS SOLITONS & FRACTALS, 2023, 177
  • [32] DOSE MANAGEMENT AND TOXICITIES IN 137 UNSELECTED PATIENTS WITH ADVANCED KIDNEY CANCER TREATED WITH SUNITINIB
    Miscoria, M.
    Tew, A.
    Baijal, S.
    Pirrie, S.
    Holmes, S.
    James, N.
    Porfiri, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 298 - 298
  • [33] Dosing Drugs in Elderly Patients With Cancer
    Ratain, Mark J.
    Hurria, Arti
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (09) : 606 - 608
  • [34] Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer
    Fujii, Masato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (02) : 220 - 229
  • [35] Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer
    Masato Fujii
    International Journal of Clinical Oncology, 2014, 19 : 220 - 229
  • [36] Managing efficacy and toxicity of drugs: Targeted delivery and excretion
    Kundu, Pronab
    Das, Sinjan
    Chattopadhyay, Nitin
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 565 : 378 - 390
  • [37] Paediatric indications and dosing guidance for advanced targeted treatments in Australia
    Mahar, Patrick D.
    Robertson, Susan J.
    Orchard, David
    Baker, Christopher
    Foley, Peter
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024, 65 (04) : 373 - 377
  • [38] Advanced approaches of developing targeted covalent drugs
    Gai, Conghao
    Harnor, Suzannah J.
    Zhang, Shihao
    Cano, Celine
    Zhuang, Chunlin
    Zhao, Qingjie
    RSC MEDICINAL CHEMISTRY, 2022, 13 (12): : 1460 - 1475
  • [39] Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer
    Schrader, AJ
    Varga, Z
    Pfoertner, S
    Goelden, U
    Buer, J
    Hofmann, R
    BJU INTERNATIONAL, 2006, 97 (03) : 461 - 465
  • [40] Precision dosing of targeted anticancer drugs-challenges in the real world
    Kim, Hannah Yejin
    Martin, Jennifer H.
    Mclachlan, Andrew J.
    Boddy, Alan V.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S1500 - S1511
12345